# Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

> **NCT02965001** · PHASE2 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 57 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** 68Ga-NOTA-AE105

## Key facts

- **NCT ID:** NCT02965001
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965001, "Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02965001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*